| Marie Lightbourne, MD | |
|
2356 Lenora Church Rd, Snellville, GA 30078-3233 | |
| (770) 972-0340 | |
| (770) 972-0379 |
| Full Name | Marie Lightbourne |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 18 Years |
| Location | 2356 Lenora Church Rd, Snellville, Georgia |
| Accepts Medicare Assignments | May be. She may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114104767 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 001826 (Georgia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Eastside Medical Center | Snellville, GA | Hospital |
| Entity Name | Jambah Group, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376849802 PECOS PAC ID: 1850565797 Enrollment ID: O20111110000787 |
News Archive
NeuroDerm, Ltd. announced today that enrollment of patients is ongoing in its second Phase II clinical trial of ND0612, a novel drug formulation for the treatment of Parkinson's disease. ND0612 is a proprietary levodopa/carbidopa liquid formulation under development for continuous subcutaneous administration through a patch pump. It is designed to provide steady levodopa blood levels for the treatment of Parkinson's disease.
Eisai Co.,Ltd. announced its latest research on evaluation about correlation of amyloid beta (Abeta) in plasma and in cerebrospinal fluid (CSF) by high precision measurement with the newly developed automated protein assay system, jointly developed with Sysmex Corporation, using full automated immunoassay system HISCLTM series for creating the simplified diagnosis of Alzheimer's disease with blood was presented at the Alzheimer's Association International Conference held in Los Angeles, California, United States, from July 14 to 18, 2019.
Scientists from the University of Southampton and Synairgen, a respiratory drug development company spun out from the University, can announce positive data from its Phase II clinical trial, into the effectiveness of the drug SNG001 (inhaled interferon beta) for asthma patients.
Transposagen Biopharmaceuticals, a leader in genetic modification technology, announced today that it has entered into a non-exclusive license agreement with Cellular Dynamics International, the world's largest producer of human induced pluripotent stem cell lines and tissue cells for drug discovery and safety.
› Verified 8 days ago
| Entity Name | Phoenix Clinic And Afterhour Care |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720569403 PECOS PAC ID: 8527317536 Enrollment ID: O20180824001418 |
News Archive
NeuroDerm, Ltd. announced today that enrollment of patients is ongoing in its second Phase II clinical trial of ND0612, a novel drug formulation for the treatment of Parkinson's disease. ND0612 is a proprietary levodopa/carbidopa liquid formulation under development for continuous subcutaneous administration through a patch pump. It is designed to provide steady levodopa blood levels for the treatment of Parkinson's disease.
Eisai Co.,Ltd. announced its latest research on evaluation about correlation of amyloid beta (Abeta) in plasma and in cerebrospinal fluid (CSF) by high precision measurement with the newly developed automated protein assay system, jointly developed with Sysmex Corporation, using full automated immunoassay system HISCLTM series for creating the simplified diagnosis of Alzheimer's disease with blood was presented at the Alzheimer's Association International Conference held in Los Angeles, California, United States, from July 14 to 18, 2019.
Scientists from the University of Southampton and Synairgen, a respiratory drug development company spun out from the University, can announce positive data from its Phase II clinical trial, into the effectiveness of the drug SNG001 (inhaled interferon beta) for asthma patients.
Transposagen Biopharmaceuticals, a leader in genetic modification technology, announced today that it has entered into a non-exclusive license agreement with Cellular Dynamics International, the world's largest producer of human induced pluripotent stem cell lines and tissue cells for drug discovery and safety.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Marie Lightbourne, MD 2356 Lenora Church Road, Snellville, GA 30078 Ph: (770) 972-0340 | Marie Lightbourne, MD 2356 Lenora Church Rd, Snellville, GA 30078-3233 Ph: (770) 972-0340 |
News Archive
NeuroDerm, Ltd. announced today that enrollment of patients is ongoing in its second Phase II clinical trial of ND0612, a novel drug formulation for the treatment of Parkinson's disease. ND0612 is a proprietary levodopa/carbidopa liquid formulation under development for continuous subcutaneous administration through a patch pump. It is designed to provide steady levodopa blood levels for the treatment of Parkinson's disease.
Eisai Co.,Ltd. announced its latest research on evaluation about correlation of amyloid beta (Abeta) in plasma and in cerebrospinal fluid (CSF) by high precision measurement with the newly developed automated protein assay system, jointly developed with Sysmex Corporation, using full automated immunoassay system HISCLTM series for creating the simplified diagnosis of Alzheimer's disease with blood was presented at the Alzheimer's Association International Conference held in Los Angeles, California, United States, from July 14 to 18, 2019.
Scientists from the University of Southampton and Synairgen, a respiratory drug development company spun out from the University, can announce positive data from its Phase II clinical trial, into the effectiveness of the drug SNG001 (inhaled interferon beta) for asthma patients.
Transposagen Biopharmaceuticals, a leader in genetic modification technology, announced today that it has entered into a non-exclusive license agreement with Cellular Dynamics International, the world's largest producer of human induced pluripotent stem cell lines and tissue cells for drug discovery and safety.
› Verified 8 days ago
Meghan Knapp, Family Medicine Medicare: Medicare Enrolled Practice Location: 1742 Oak Rd, Snellville, GA 30078 Phone: 770-638-1401 | |
Lina S Hwang, DO Family Medicine Medicare: May Accept Medicare Assignments Practice Location: 3555 Centerville Hwy Ste 100, Snellville, GA 30039 Phone: 770-985-9957 | |
Dr. Gordon Glenn Freeman, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 3891 Highway 78 W, Snellville, GA 30039 Phone: 770-972-4764 Fax: 770-972-4164 | |
Dr. Cheryl A Copas, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1550 Janmar Rd # B, Snellville, GA 30078 Phone: 770-979-9331 Fax: 770-979-8827 | |
Dr. Yong S Kim, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1742 Oak Rd, Snellville, GA 30078 Phone: 770-638-1401 Fax: 770-638-1402 | |
Sunday A Fawole, DDS, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2395 Scenic Hwy S, Snellville, GA 30078 Phone: 678-377-6830 Fax: 678-377-6836 |